Shanghai-based Huihe Healthcare, a developer of structural heart disease intervention medical devices, announced receiving marketing approval in China for its K-Clip transcatheter tricuspid valve repair system. This approval marks a significant milestone in the treatment of tricuspid regurgitation.
Innovation and Market Impact
K-Clip is the first of its kind in China and represents a groundbreaking advancement in the global treatment of tricuspid regurgitation through transcatheter tricuspid valve annuloplasty (TTVA). This innovative system offers a less invasive treatment option, potentially improving patient outcomes and reducing recovery times.-Fineline Info & Tech
Leave a Reply